Themis Medicare Limited
Themis Medicare is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.
What Themis files
- Others53
- Important11
- Board Meeting11
- PPTs7
- Updates7
- Pledging3
Here's a concise summary of the investor presentation: **Business Performance:** Themis Medicare's Q1 FY27 consolidated revenue dipped 10.9% YoY to ₹86.96 Cr, mainly due to API business headwinds. Despite this, profitability saw a significant turnaround. PAT surged to ₹24.6 Cr from a ₹14.2 Cr loss in Q1 FY26, yielding a...
Here's a concise summary of Themis Medicare's latest investor presentation: 1. **Business Performance:** Themis Medicare reported a strong Q4 FY26 comeback. Revenue grew 6.7% YoY to ₹76.5 Cr. EBITDA soared to ₹3.8 Cr (4.9% margin) from a ₹5.8 Cr loss last year, with PAT turning profitable at ₹8.9 Cr (11.6%...
Here's a concise, retail-friendly summary: **Business Performance:** Themis Medicare faced significant headwinds from its high-margin formulations business. Q2 FY26 revenue fell to ₹78 Cr (-33.3% YoY), with PAT down 125.3%. H1 revenue declined 26.8% YoY, and PAT dropped 145.8%. Positively, H1 API business grew 31% YoY, and Trade business rose...
**1. Financial Highlights:** Q1 FY26 saw revenue at Rs. 97.58 Cr, down from Rs. 122.99 Cr year-on-year, impacted by a high-margin business disruption. The company reported a Q1 PAT loss of Rs. 14.22 Cr and an EBITDA loss of Rs. 10.08 Cr. Despite this, the balance sheet remains strong, with...
1. Financial Highlights: Themis Medicare reported FY25 revenue of Rs. 405.5 Cr, up 6.2% YoY, fueled by a 20.4% rise in Formulations and over 11% growth in Hospital and Trade segments. Gross margin expanded sharply by 300 bps to 67.45%, though EBITDA margin declined to 12.1% from 13.5% due to...